Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
AUPH - Aurinia Pharmaceuticals Inc
Market Cap 1.45B P/E - EPS this Y 105.86% Ern Qtrly Grth -
Income -22.55M Forward P/E -24.12 EPS next Y 1,715.60% 50D Avg Chg -1.00%
Sales 220.36M PEG - EPS past 5Y - 200D Avg Chg 17.00%
Dividend N/A Price/Book 3.71 EPS next 5Y - 52W High Chg -19.00%
Recommedations - Quick Ratio 4.89 Shares Outstanding 143.18M 52W Low Chg 149.00%
Insider Own 7.21% ROA -2.16% Shares Float 128.87M Beta 1.46
Inst Own 42.65% ROE -5.78% Shares Shorted/Prior 5.53M/6.88M Price 10.13
Gross Margin 76.86% Profit Margin -10.23% Avg. Volume 2,400,288 Target Price 10.84
Oper. Margin 17.34% Earnings Date Feb 13 Volume 3,720,896 Change -3.06%
Healthcare | Biotechnology | Canada
About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc News
12/11/24 Exploring Three High Growth Tech Stocks In The United States
12/10/24 Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
09:54 AM While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership
11/18/24 Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
11/15/24 Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
11/14/24 Aurinia to Participate in Jefferies London Healthcare Conference
11/08/24 Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets
11/08/24 Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
11/07/24 Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates
11/07/24 Aurinia: Q3 Earnings Snapshot
11/07/24 Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
11/07/24 Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
11/02/24 Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago
10/30/24 Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
10/11/24 Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
09/27/24 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability
09/24/24 Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
09/13/24 Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
09/12/24 Aurinia Announces Board Restructuring
09:04 AM Top High Growth Tech Stocks To Watch In September 2024
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Jayne David R.W. Director Director May 18 Sell 11.26 8,733 98,334 49,310 05/23/23
Hagan Joseph P Director Director May 18 Sell 10.58 272 2,878 11,961 05/23/23
Billen Daniel Director Director May 18 Sell 11.26 4,650 52,359 33,393 05/23/23
MacKay-Dunn R. Hector Director Director May 18 Sell 11.26 4,818 54,251 24,225 05/23/23
Leversage Jill Director Director May 18 Sell 11.26 4,815 54,217 18,528 05/23/23
Jayne David R.W. Director Director May 18 Option 3.62 10,000 36,200 40,000 07/11/22
MacKay-Dunn R. Hector Director Director Mar 09 Buy 10.997 5,000 54,985 11,000 03/11/22
MILNE GEORGE M JR Director Director Mar 04 Buy 10.82 5,000 54,100 50,000 03/08/22